Inhaled prostacyclin analogue iloprost is currently utilized in adult patients with pulmonary arterial hypertension (PAH), but little information is available on its use in the pediatric population. This study evaluated the safety and acute haemodynamic effects of inhaled iloprost in children with PAH associated with congenital heart disease (CHD). Children with PAH-CHD who underwent cardiac catheterization and iloprost administration in our catheter laboratory between June 2007 and October 2015 were included. Iloprost was administered by atomization inhalation and changes in hemodynamic parameters were recorded. In total, 100 children with PAH-CHD were enrolled. Median age was 13 [1.5-18.0] years and 34% were male. A ventricular septal defect was present in 84%, a patent duct in 12%, a complete atrioventricular septal defect in 2%, and an isolated atrial septal defect in 2%. Pulmonary vascular resistance indexed (PVRI) was above 8 WU m 2 in 96% and was above a third systemic (R p /R s > 0.33) in 97%. Iloprost was well tolerated in all patients. Following iloprost inhalation, mean pulmonary arterial pressure decreased from 78.4 ± 9.2 to 72.8 ± 10.8 mmHg (p < 0.01) and pulmonary-to-systemic blood flow ratio (Q p /Q s ) increased from 1.12 ± 0.48 to 1.37 ± 0.63 (p < 0.01), with no change in cardiac index (Q s ). PVRI decreased from 21.0 ± 9.0 to 16.9 ± 8.0 WU m 2 (p < 0.01) following inhalation but 92% patients still had a PVRI > 8 WU m 2 and 93% an R p /R s > 0.33. Acute inhalation of iloprost in children with PAH associated with CHD resulted in a significant improvement in hemodynamic parameters. Despite this, few patients achieve strict criteria of operability, underscoring the importance of early screening and timely repair of CHD.
Introduction
Pulmonary arterial hypertension (PAH) is a rare disease with an unfavorable prognosis, characterized by increases in pulmonary arterial pressure (PAP) and pulmonary vascular resistance (PVR). Currently, disease-targeting therapies, acting on the three pathways which drive vasoconstriction and proliferation in the pulmonary vascular tree, have revolutionized the management of PAH, with numerous randomized trials demonstrating their efficacy in adults with PAH. Prostacyclin analogues were the first drugs to be used in this setting and remain fundamental in the management of PAH patients with advanced disease [1] .
Iloprost is a prostacyclin analogue, which can be administered by inhalation and has been shown to effectively lower pulmonary arterial pressure and pulmonary vascular resistance in PAH patients, while having little effect on the systemic circulation [2] [3] [4] [5] [6] [7] . However, very little is known on the effects of inhaled iloprost in children with PAH associated with congenital heart disease (PAH-CHD) [8, 9] . In CHD, acute reversibility is used in the catheter lab to assessing the severity of pulmonary vascular disease and support the decision to operate patients with unrepaired defects. Current pulmonary hypertension guidelines recommend using Pulmonary vascular resistance indexed (PVRI) as a guide for deciding whether systemic-to-pulmonary shunts are "correctable" (PVRI < 4 WU m 2 ) or not (PVRI > 8 WU m 2 ). Previous authors have recommended using the ratio of pulmonary to systemic resistance (R p /R s ), but a robust cut-off is still lacking: while an R p /R s < 0.66 (R p less than two-thirds systemic) is able to exclude patients with severe pulmonary vascular disease, an R p /R s < 0.33 (Rp less than one-thirds systemic) appears to be a safer, albeit more conservative cut-off [10] .
This study aimed to evaluate the safety and effect of acute iloprost inhalation in children with PAH-CHD undergoing cardiac catheterization, in relation to currently recommended hemodynamic cut-offs for operability.
Methods

Patients
Children with PAH-CHD aged 0-18 years who underwent cardiac catheterization in the Department of Pediatric Cardiology of Beijing Anzhen Hospital between June 2007 and October 2015 were included in the study. Patients with an atrial septal defect (ASD), ventricular septal defect (VSD), patent ductus arteriosus (PDA), or atrioventricular septal defect (AVSD) were included, while patients with other more complex CHD were excluded. Moreover, patients deemed to have PAH-CHD with a small/coincidental defect, and those with post-operative PAH-CHD were also excluded [11] . Clinical and demographic characteristics for all patients at the time of cardiac catheterization were collected from clinical records. Informed consent to cardiac catheterization was provided for all procedures.
Cardiac Catheterization and Iloprost Administration
All patients underwent right and left cardiac catheterization. Right heart catheterization was performed to record the pressure and/or oxygen saturations in the inferior vena cava, superior vena cava, right atrium, right ventricle, main pulmonary artery, and left pulmonary artery, as well as pulmonary capillary wedge pressure (PCWP). Left heart catheterization was performed to measure pressure and oxygen saturations in the ascending and descending aorta, and left ventricle. Pulmonary blood flow (Q p ) and systemic cardiac output (Q s ) were estimated using the indirect Fick method [12] . PVRI and the ratio of pulmonary to systemic vascular resistance (R p /R s ) were, thereafter, calculated.
After baseline haemodynamics were acquired, inhaled Iloprost was administered at a dose of 20 µg, with the exception of children aged < 3 years of age or those weighing < 15 kg who received 10 µg. The medication was inhaled via a mask using a Bi-Sonic air compressor pump (PARI TurboBOY N model; PARI; Starnberg, Germany) as an atomization generator. During inhalation, percutaneous systemic oxygen saturations, aortic, and pulmonary arterial pressures were continuously monitored, and adverse reactions were recorded. Atomization continued until all of the medication had been inhaled. The entire inhalation process took 15-20 min and, thereafter, left-and right heart cardiac catheterization was repeated (20-min time point).
Statistical Methods
All statistical analyses were performed using SPSS Statistics (IBM Corporation, Armonk, New York) and R version 3.3.0 (R Foundation for Statistical Computing, Vienna, Austria, 2016). Continuous variables are described as mean ± standard deviation or median [range] and categorical variables as number (percent). The Kolmogorov-Smirnov test was used to determine whether data were normally distributed. The paired t test or Wilcoxon signed-rank test was used to compare the hemodynamic parameters before and after iloprost inhalation. Logistic regression analysis was used to assess the relation between significant hemodynamic response to iloprost and baseline characteristics. A p value < 0.05 was considered indicative of statistical significance.
Results
Patient Population
A total of 100 children were included. Median age was 13 [1.5-18 .0] years, and 34 (34%) were male. Six (6%) patients had Down syndrome. A VSD was present in 84 (84%) patients, with a median defect size on echocardiography of 19 [6.0-36.0] mm. Among these, 48 had an isolated VSD, while in the remainder this was associated with a PDA and/ or an ASD. Twelve (12%) patients had PDA with a median size of 8.5 [5.0-12.0] mm, 2 (2%) patients had a complete AVSD, and two patients had an isolated ASD (defect sizes 16.0 and 28.0 mm). Mean percutaneous oxygen saturation was 88.6 ± 4.6% (range 67-97%), with 63% of patients having resting saturations of 90% or below. The vast majority were mildly symptomatic: 93 (93%) patients were in NYHA Functional Class II and 7 (7%) were in Class III. Forty seven (47%) patients were receiving treatment with PAH therapies prior to cardiac catheterization, including oral bosentan in 24 (51.0% of those receiving therapy), oral beraprost in 4 (8.5%), and sildenafil or vardenafil or tadalafil in 13 (27.7%). Six (12.8%) patients were on combination therapy.
Baseline Hemodynamic Characteristics
At baseline, mean PAP (mPAP) was 78.4 ± 9.2 mmHg ( Table 1 ). The ratio of pulmonary arterial pressure to systemic arterial pressure (P p /P s ) was 0.93 ± 0.08. Q p /Q s was 1.12 ± 0.48, with 93 (93%) patients having a Q p /Q s below 2 and 86 (86%) below 1.5. Average PVRI was 21.0 ± 9.0 WU m 2 with 96 (96%) patients having a PVRI > 8 WU m 2 , 2 (2%) between 4 and 8 WU m 2 , and 2 (2%) having a "normal" PVRI < 4 WU m 2 . R p /R s was 0.91 ± 0.38, with 24 (24%) patients having an R p /R s < 0.66 and 3 (3%) an R p /R s < 0.33. There was no significant relation between PAH therapy and baseline parameters.
Response to Inhaled Iloprost
Following inhalation of iloprost, mPAP dropped by an average 7.0%, from 78.4 ± 9.2 to 72.8 ± 10.8 mmHg (p < 0.001), while there was only a slightly drop (average 2.7%) in mean systemic arterial pressure (mSAP) from 84.4 ± 10.9 to 81.7 ± 10.1 mmHg (p = 0.002, Table 1 ). The ratio of mean pulmonary arterial pressure to mean systemic arterial pressure (P p /P s ) dropped by an average 3.8% (p < 0.001) and the PCWP increased slightly from 10.2 mmHg to 10.7 mmHg (p = 0.037). There was no change in cardiac index (Q s , p = 0.073), but Q p /Q s increased from 1.12 ± 0.48 to 1.37 ± 0.63 (p < 0.001). In 16 (16%) patients with a baseline Q p /Q s < 1.5, this increased to > 1.5, and in 3 (3.0%) patients Q p /Q s increased to > 2.
Average PVRI decreased by 20.0% from 21.0 ± 9.0 to 16.9 ± 8.0 WU m 2 (p < 0.001). A drop in PVRI > 20% was observed in 49 (49%) patients (responders), while 51 (51%) patients had no significant response to iloprost (non-responders, drop in PVRI < 20%). There were no significant differences between responders and nonresponders in terms of their baseline clinical and haemodynamic characteristics (Table 2 ). There was no relation between patients achieving a PVRI drop > 20% and age, sex, body surface area (BSA), or baseline PVRI. Only 4 (4%) patients with a PVRI > 8 at baseline dropped their PVRI to < 8 WU m 2 and no one to ≤ 4 WU m 2 . Two (2%) patients with a PVRI between 4 and 8 dropped their PVRI to < 4 WU m 2 . Rp/Rs decreased from 0.92 ± 0.37 at baseline to 0.73 ± 0.33 (p < 0.001), with only 2% and 4% of patients with a baseline R p /R s > 0.66 and > 0.33 dropping their R p /R s to < 0.33.
A greater response to iloprost was observed in patients who were treatment-naive at baseline compared to patient already on PAH therapies: R p /R s dropped by an average of 8.8% in the latter compared to 24.5% in the treatment-naive group (p = 0.003). There was also a trend towards a greater average drop in PVRI in treatment-naive patients (21.5 vs. 13.9% in treated patients, p = 0.052). Average Q p /Q s also increased more in treatment-naive patients (32.9 vs. 14.4%, p = 0.012).
Seven patients with a PVRI < 8 WU m 2 after iloprost inhalation and 9 patents with PVRI between 8 and 14 WU m 2 after iloprost inhalation underwent corrective operation after cardiac catheterization. One patient with a VSD and PDA (PVRI after iloprost inhalation 29 WU m 2 ) underwent percutaneous PDA occlusion. All were alive on completion of the data collection (median follow-up time after surgery or intervention was 3.6 years [range 1.1-6.4 years]). 
Adverse Events
Cardiac catheterization was performed under local anesthesia in 66 (66%) and sedation in 34 (34%) patients, while none received general anesthesia with tracheal intubation. Iloprost inhalation was well tolerated in most patients. Two children who received sedation developed wheezing during iloprost inhalation, associated with laborious breathing and a drop in peripheral oxygen saturations; in both, iloprost inhalation was interrupted and they improved promptly following oxygen administration. Facial flushing occurred in 70 (70%) patients, while there were no cases of significant hypotension (defined as a drop in systolic blood pressure > 20 mmHg, associated with symptoms such as dizziness or clammy skin). No patients experienced headache, jaw pain, or cough.
Discussion
We examined the acute effects of iloprost inhalation in a pediatric population of patients with PAH-CHD, which was significantly larger than previous reports. [8, 13] Inhalation of iloprost during cardiac catheterization was overall safe and resulted in an improvement in pulmonary hemodynamics in this population, despite baseline hemodynamics suggestive of significant pulmonary vascular disease in the vast majority of patients (average R p /R s 0.92 ± 0.37). Significant vasoreactivity was more pronounced in patients who were treatment-naive, and to a lesser extent in patients already on treatment with PAH therapies. However, only a minority of patients in this cohort with unrepaired CHD achieved the hemodynamic criteria that are currently recommended for defining operability. Cardiac catheterization with vasoreactivity testing plays an important role in the management of children with CHD and, in particular, in establishing which patients are going to benefit from repair of their defect, as opposed to those in whom significant pulmonary vascular disease is established and who should not undergo repair. PVRI and R p /R s are particularly important in this setting. International guidelines and previous authors have suggested using a PVRI < 4 or R p /R s < 0.33 for defining patients who are safe to undergo repair. While a pulmonary vasodilator challenge is recommended in patients with raised PVR or R p /R s , little is known on the response to pulmonary vasodilators in PAH-CHD, especially in the pediatric setting. Significant vasoreactivity (PVRI drop > 20%) was observed in one-half of our patients, despite the vast majority (96.0%) having a PVRI > 8 WU m , which according to current PH guidelines, suggests established pulmonary vascular disease. The clinical significance of acute vasoreactivity in established PAH-CHD is still debated. Previous studies have reported acute vasoreactivity in cohorts of patients with Eisenmenger syndrome and a relation between vasoreactivity and clinical outcome. It remains, however, unknown whether acute vasoreactivity is a marker of residual compliance of the pulmonary vascular tree and, perhaps, a less severe form of pulmonary vascular disease [14] . Moreover, even though PAH therapies have been shown to improve survival in Eisenmenger syndrome, the relation between acute vasoreactivity and longterm response to PAH therapies remains unclear [15] . In our study, patients on PAH therapies responded less well to iloprost compared to treatment-naive patients, suggesting that acute administration of iloprost may be able to detect the vasodilator potential of PAH therapies in PAH-CHD patients.
Despite a significant proportion of patients experiencing a drop in PVRI after iloprost challenge in our study, few patients reached criteria for operability, as defined by current pulmonary hypertension guidelines. The majority of patients in our cohort had post-tricuspid defects (VSD, AVSD, or PDA) and all were above the age of 1.5 years. Our data confirm the importance of early diagnosis of CHD and timely repair, in order to avoid the development of PAH and achieve an optimal long-term outcome. Once PAH-CHD is established, the perioperative risk and long-term outcome are guarded, as PAH is likely to progress despite defect repair. Data from adult PAH-CHD cohorts suggest that patients with repaired PAH-CHD have a far worse outcome compared to Eisenmenger patients and those with systemic-topulmonary shunts [16] . The cut-offs for PVRI suggested by the recent PH guidelines confirm the current trend towards a more conservative approach to PAH-CHD with regards to operability. Indeed, the PVRI cut-off of < 4 WU m 2 is equivalent to normal (or near-normal hemodynamics). In our cohort, 17 patients underwent repair despite some having higher than recommended PVRI. While there was no death in the short-term, longer-term follow data are required and are being collected.
Several agents are suggested by international PH and ACHD guidelines for use in acute vasoreactivity testing (inhaled NO, oxygen, and aerosolized or intravenous prostanoids), albeit with different indications in idiopathic PAH versus PAH-CHD [17] [18] [19] . Unfortunately, inhaled NO is not available in China and oxygen, which was widely used as vasodilatory agent in previous decades, is currently not advocated as a standalone agent of vasoreactivity testing. Iloprost appears to be a valid alternative to NO and was approved as a pulmonary vasodilator in China in 2007. It can be administered easily by simple nebulization and requires minimal equipment. Under conditions of ventilator-assisted breathing, the dose provided by the inhaler with a controllable flow rate is 25 ng/kg/min [13, 20] . As none of the children in this study underwent tracheal intubation, the PARI BOY N model atomizer was used as an atomization generator, with inhalation via a mask at a single dose of 0.3-0.5 µg/kg in children [17] . In order to ensure that the medication was adequately delivered, a dose of 20 µg of iloprost was diluted in 1 mL of normal saline and atomization inhalation took place over 15-20 min. Half of this dose (10 µg) was given to children younger than 3 years of age and those who weighed less than 15 kg.
Common side effects of prostacyclin use include headache, coughing, local flushing, and jaw pain, as well as a decrease in systemic arterial pressure [11, 21] . The most common side effect in our cohort was facial flushing, seen in 70% of patients. While an on-going upper respiratory tract infection or adverse reaction to other medication used around the procedure may have been the cause for bronchospasm in two of our patients, interruption of iloprost led to a prompt improvement suggesting a possible idiosyncratic reaction to this drug. Reassuringly, there were no other serious adverse events.
Limitations of This Study
This study focused on part of the wide spectrum of PAH-CHD. Indeed, several types of congenital systemicto-pulmonary shunts can lead to the development of PAH. Our cohort included patients with a VSD, PDA, ASD, or AVSD, and patients with either Eisenmenger syndrome or PAH in the presence of a left-right shunt (groups 1 and 2 of the international PAH-CHD classification), while patients with small defects or previously repaired defects (groups 3 and 4) were excluded. However, the patients included in our study represent the vast majority of PAH-CHD patients and provide a picture of this condition that is not confounded by very complex cardiac anatomy, prior surgery or intervention, or an intrinsic predisposition of the pulmonary circulation towards pulmonary vascular disease (idiopathic PAH-like condition, group 3 of the PAH-CHD classification) [22] .
This study only considered the acute effect of iloprost, used over a short period during cardiac catheterization. The long-term effectiveness and safety of iloprost in children with PAH-CHD, as well as other forms of PAH in the pediatric population, requires further investigations. However, our study provides valuable information on the safety profile of iloprost in pediatric PAH-CHD in a large patient population, and provides insight into pulmonary vasoreactivity in this condition.
Conclusions
This study in 100 children with PAH associated with systemic-to-pulmonary shunt type CHD showed that short-term iloprost inhalation is well tolerated and has significant effects on haemodynamic parameters, including pulmonary vascular resistance and pulmonary blood flow. Despite this, few patients achieve strict criteria of operability, underscoring the importance of early screening and timely repair of CHD.
